{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:59:34Z","timestamp":1787245174991,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.semarthrit.2017.03.024","type":"journal-article","created":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T11:30:16Z","timestamp":1491046216000},"page":"165-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis"],"prefix":"10.1016","volume":"47","author":[{"given":"Laura C.","family":"Cappelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy Lynn","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Clifton O.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.03.024_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-006-0275-5","article-title":"Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA","volume":"26","author":"Agrawal","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/rheumatology\/kei203","article-title":"Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome","volume":"45","author":"Quinn","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib4","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3899\/jrheum.140082","article-title":"Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis","volume":"41","author":"Barra","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib5","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/art.30596","article-title":"Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment","volume":"63","author":"Lal","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.131279","article-title":"Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry","volume":"41","author":"De Keyser","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","article-title":"Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the \u2018Orencia and Rheumatoid Arthritis\u2019 registry","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2017.03.024_bib9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/annrheumdis-2014-205850","article-title":"IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis","volume":"75","author":"Anderson","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2011-200968","article-title":"A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease","volume":"71","author":"Pratt","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3899\/jrheum.111284","article-title":"Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations","volume":"39","author":"Seddighzadeh","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clim.2015.03.025","article-title":"IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients","volume":"158","author":"Ortiz","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib13","first-page":"460","article-title":"Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre","volume":"32","author":"Addimanda","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reuma.2016.03.014","article-title":"Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice","volume":"13","author":"Notario Ferreira","year":"2017","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.semarthrit.2017.03.024_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216303705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216303705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T22:23:35Z","timestamp":1535927015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216303705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0049017216303705"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.024","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}